Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PHAT
stocks logo

PHAT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
55.88M
+88.39%
-0.390
-62.86%
59.94M
+110.19%
-0.406
-69.01%
72.78M
+84.24%
-0.280
-73.33%
Estimates Revision
The market is revising Upward the revenue expectations for Phathom Pharmaceuticals, Inc. (PHAT) for FY2025, with the revenue forecasts being adjusted by 2.01% over the past three months. During the same period, the stock price has changed by 19.12%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4%
In Past 3 Month
Stock Price
Go Up
up Image
+19.12%
In Past 3 Month
Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 27.67 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 27.67 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.700
sliders
Low
26.00
Averages
27.67
High
29.00
Current: 14.700
sliders
Low
26.00
Averages
27.67
High
29.00
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$17 -> $22
2025-10-31
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$17 -> $22
2025-10-31
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Phathom Pharmaceuticals to $22 from $17 and keeps a Buy rating on the shares. The firm notes the company delivered a solid beat on both revenue and expense discipline as the company pivots away from direct-to-consumer sales and focuses on GI specialists. FY2025 revenue guidance was raised at the midpoint to $170M-$175M from $165M-$175M, and management reiterated expectations for operating profitability in 2026.
H.C. Wainwright
Buy
upgrade
$20 -> $26
2025-10-31
Reason
H.C. Wainwright
Price Target
$20 -> $26
2025-10-31
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Phathom Pharmaceuticals to $26 from $20 and keeps a Buy rating on the shares following the Q3 report.
Cantor Fitzgerald
NULL
to
Overweight
upgrade
$23 -> $29
2025-06-06
Reason
Cantor Fitzgerald
Price Target
$23 -> $29
2025-06-06
upgrade
NULL
to
Overweight
Reason
Needham
Joseph Stringer
Strong Buy
Reiterates
$28
2025-04-21
Reason
Needham
Joseph Stringer
Price Target
$28
2025-04-21
Reiterates
Strong Buy
Reason
Goldman Sachs
Paul Choi
Hold
Maintains
$12 → $10
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$12 → $10
2025-04-17
Maintains
Hold
Reason
Needham
Joseph Stringer
Strong Buy
Reiterates
$28
2025-04-09
Reason
Needham
Joseph Stringer
Price Target
$28
2025-04-09
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT.O) is -11.82, compared to its 5-year average forward P/E of -4.10. For a more detailed relative valuation and DCF analysis to assess Phathom Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.10
Current PE
-11.82
Overvalued PE
-0.90
Undervalued PE
-7.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
27.66
Undervalued EV/EBITDA
-26.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
119.44
Current PS
0.00
Overvalued PS
342.30
Undervalued PS
-103.42
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PHAT News & Events

Events Timeline

(ET)
2025-11-04
08:10:37
Phathom Reports First Patient Dosed in Phase 2 pHalcon-EoE-201 Study
select
2025-10-30 (ET)
2025-10-30
07:03:34
Phathom Pharmaceuticals expects to have enough cash to support operations through 2026.
select
2025-10-30
07:02:51
Phathom Pharmaceuticals announces Q3 adjusted EPS of 15 cents, falling short of consensus estimate of 41 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-12NASDAQ.COM
Unexpected 12-Month Forecast for ITOT by Analyst

  • ETF Analyst Target Price: The iShares Core S&P Total U.S. Stock Market ETF (ITOT) has an implied analyst target price of $169.10, indicating a potential upside of 13.49% from its current trading price of $149.00.

  • Notable Holdings with Upside: Key underlying holdings of ITOT, such as Phathom Pharmaceuticals (PHAT), OOMA Inc (OOMA), and Atlanta Braves Holdings (BATRA), show significant upside potential, with target prices suggesting increases of 61.04%, 57.71%, and 33.15%, respectively.

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industries.

  • Further Research Needed: Investors are encouraged to conduct additional research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.

[object Object]
Preview
7.0
10-30SeekingAlpha
Phathom anticipates $1B opportunity in GI market as sales restructuring boosts revenue by 25%

  • Management Changes and Financial Performance: Phathom Pharmaceuticals reported a 25% growth in Q3 2025 net revenue, reaching $49.5 million, while significantly reducing operating expenses by 43%. CEO Steven Basta introduced new leadership members to strengthen the company's commercial strategy.

  • Strategic Focus on Gastroenterology: The company is shifting its sales strategy to prioritize gastroenterology prescribers, with a realignment of sales territories and incentives aimed at accelerating growth in 2026.

  • Updated Financial Guidance: Management narrowed its full-year revenue guidance to $170 million to $175 million and expects to maintain cash operating expenses below $55 million in Q4, indicating confidence in achieving operating profitability by 2026.

  • Analyst Sentiment and Risks: While analysts expressed optimism about Phathom's growth, they raised concerns regarding prescription trends, cost management sustainability, and the challenges of changing long-standing prescribing habits among physicians.

[object Object]
Preview
9.5
10-30SeekingAlpha
Phathom Pharmaceuticals surpasses revenue and earnings expectations; revises FY25 forecast

  • Q3 Financial Performance: Phathom Pharmaceuticals reported a Q3 non-GAAP EPS of -$0.15, beating expectations by $0.26, with revenue of $49.5 million, a 202.8% increase year-over-year, surpassing estimates by $2.51 million.

  • Cash Position and Projections: As of September 30, 2025, the company had $135.2 million in cash and equivalents, with a net cash usage of approximately $14 million in Q3, showing a 77% improvement from the previous quarter, and believes it can achieve operating profitability in 2026 without additional equity financing.

  • Updated Revenue Guidance: Phathom updated its full-year 2025 revenue guidance to between $170 million and $175 million, slightly below the consensus estimate of $170.4 million.

  • Growth Focus: The company is focusing on accelerating GI sales to boost the growth of its product VOQUEZNA, projecting revenues of $165 million to $175 million for 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Phathom Pharmaceuticals Inc (PHAT) stock price today?

The current price of PHAT is 14.7 USD — it has increased 0.2 % in the last trading day.

arrow icon

What is Phathom Pharmaceuticals Inc (PHAT)'s business?

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

arrow icon

What is the price predicton of PHAT Stock?

Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 27.67 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Phathom Pharmaceuticals Inc (PHAT)'s revenue for the last quarter?

Phathom Pharmaceuticals Inc revenue for the last quarter amounts to 49.50M USD, increased 202.74 % YoY.

arrow icon

What is Phathom Pharmaceuticals Inc (PHAT)'s earnings per share (EPS) for the last quarter?

Phathom Pharmaceuticals Inc. EPS for the last quarter amounts to -0.41 USD, decreased -68.94 % YoY.

arrow icon

What changes have occurred in the market's expectations for Phathom Pharmaceuticals Inc (PHAT)'s fundamentals?

The market is revising Upward the revenue expectations for Phathom Pharmaceuticals, Inc. (PHAT) for FY2025, with the revenue forecasts being adjusted by 2.01% over the past three months. During the same period, the stock price has changed by 19.12%.
arrow icon

How many employees does Phathom Pharmaceuticals Inc (PHAT). have?

Phathom Pharmaceuticals Inc (PHAT) has 427 emplpoyees as of December 05 2025.

arrow icon

What is Phathom Pharmaceuticals Inc (PHAT) market cap?

Today PHAT has the market capitalization of 1.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free